Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

Masatoshi Kudo

doi:10.1159/000512170

Abstract

1 min read

the PD-1/PD-L1 pathway have a limited impact because they do not produce the synergistic inhibitory effects on VEGF-A or WNT/-catenin mutation that are obtained with combination therapy using an ICI plus an anti-VEGF antibody or TKIs.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Dataset

Supplementary Material for: Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody

Masahiro Morita, Naoshi Nishida, Kazuko Sakai, Tomoko Aoki, Hirokazu Chishina, Mashiro Takita, Ida H., Shingo Hagiwara, Yasunori Minami, Kazuomi Ueshima, Kazuto Nishio, Yukari Kobayashi, Kazuhiro Kakimi, Masatoshi Kudo

Article2020

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma

Masatoshi Kudo

Article2023

Incidence of Hyper Progressive Disease in Combination Immunotherapy and Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Monotherapy for Unresectable Hepatocellular Carcinoma

Tomoko Aoki, Masatoshi Kudo, Kazuomi Ueshima, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Hiroshi Ida, Yasunori Minami, Masakatsu Tsurusaki, Naoshi Nishida

Article2021

Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody

Masahiro Morita, Naoshi Nishida, Kazuko Sakai, Tomoko Aoki, Hirokazu Chishina, Masahiro Takita, Hiroshi Ida, Satoru Hagiwara, Yasunori Minami, Kazuomi Ueshima, Kazuto Nishio, Yukari Kobayashi, Kazuhiro Kakimi, Masatoshi Kudo

Editorial Material2018

Combination Cancer Immunotherapy in Hepatocellular Carcinoma

Masatoshi Kudo